Why Everyone Is Talking About GLP-1 Skincare (And What It Means for Your Clinical Study)
The rapid rise of GLP-1 receptor agonists like Ozempic and Wegovy has introduced a new concern in the beauty space: what many are calling “GLP-1 face.”
This isn’t just a social media trend. It reflects a real and rapid shift in skin physiology driven by significant weight loss. As a result, brands are beginning to position products to restore volume, improve firmness, and address visible skin changes associated with these medications.
But supporting those claims requires more than standard anti-aging testing.
Understanding the “Four Ds” of GLP-1 Skin
The skin changes associated with GLP-1 use differ from gradual, chronological aging. They are often described using the “Four Ds”:
• Deflation: Loss of underlying fat that supports facial contours
• Deep Wrinkles: Structural collapse leading to more pronounced lines
• Dehydration: Increased dryness and compromised barrier function
• Density Loss: Reduced collagen support and skin resilience
These changes can occur over a relatively short period, making them more difficult to address with conventional formulations.
Why Standard Anti-Aging Testing May Not Be Enough
Most clinical studies of anti-aging products are conducted in the general population, typically women aged 40 to 65 experiencing gradual skin aging.
GLP-1 users represent a different physiological subset. Rapid weight loss can introduce changes that are not captured in traditional study designs.
As a result, outcomes observed in a general population may not translate to individuals experiencing these accelerated changes. A product that demonstrates improvement in firmness or elasticity in a standard study may show reduced or no measurable effect in this group.
Considerations for Clinical Study Design
For brands developing products targeted toward this population, study design becomes critical. Considerations may include:
• Subject selection: Individuals with recent, significant weight loss
• Endpoints: Measures that reflect structural and functional skin changes (e.g., elasticity, firmness, hydration)
• Study duration: Sufficient time to assess meaningful improvements
• Claim alignment: Ensuring claims accurately reflect what is being measured
Aligning these elements helps ensure that study outcomes are relevant and supportable.
The Bottom Line
As GLP-1 medications continue to gain popularity, the demand for skincare solutions addressing associated skin changes will likely increase.
This is not just a new claim category; it’s a different testing scenario. Approaching it with standard anti-aging frameworks may not produce meaningful or defensible results.
A more tailored clinical approach, one that starts with the right population and aligns endpoints with the biology behind these changes, will be essential for brands looking to support credible claims in this space.
If you are developing products targeting GLP-1 related skin concerns and need support with clinical study design or claim substantiation, feel free to reach out at Hello@orivida-research.com.